Abstract: The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.

Abstract: The present application relates to extracting a plurality of compounds from a traditional Chinese medicine, or synthesizing a compound capable of promoting nucleic acid delivery, and utilizing the extracted compound, or a plurality of combinations to promote absorption and entry of a nucleic acid such as sRNA into a target cell, and to facilitate the entry of a nucleic acid into a target site in a subject in need thereof

Abstract: A system and method for producing an oil-in-water (“O/W”) emulsion performs or includes the steps of: a) providing an oil phase and a water phase, b) premixing the oil phase and the water phase to form an O/W pre-emulsion, and c) homogenizing the O/W pre-emulsion to form an O/W emulsion by at least one counter-jet disperser.

Abstract: This disclosure relates to a drug delivery system comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, a tumor necrosis factor-? (TNF-?) or TNF receptor (TNFR) inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease (caspase) inhibitor, including any combination of these compounds and, optionally, a sustained delivery component. This type of drug delivery system can be used to treat a medical condition such as an inherited or age-related choroid, retina, optic nerve disorder, or optic nerve degeneration; an otic disorder; a neurologic or CNS disorder; or a related condition; or a condition related to occlusion or obstruction of a blood vessel or blood circulation such as a stroke, myocardial or renal infarction. Medicaments, methods of manufacturing medicaments, kits, and other related products or methods are also described.

Abstract: The present application provides bifunctional compounds of Formula (X): or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for Bruton's tyrosine kinase (BTK). The present application also relates to methods for the targeted degradation of BTK through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to BTK which can be utilized in the treatment of disorders modulated by BTK.

Abstract: Disclosed herein are polymeric methylprednisolone conjugates and prodrugs as well as method of using the same. Disclosed herein are methods of treating a spinal cord injury in a subject comprising: systemically delivering a composition comprising a polymeric methylprednisolone conjugate to the subject. Disclosed herein are methods of enhancing neuroprotection in a subject after spinal cord injury comprising systemically delivering a composition comprising a polymeric methylprednisolone conjugate to the subject.

Abstract: A macromolecule includes i) a dendrimer comprising a core and at least one generation of building units, the outermost generation of building units having surface amino groups wherein at least two different terminal groups are covalently attached to the surface amino groups of the dendrimer, ii) a first terminal group which is a residue of a pharmaceutically active agent comprising a hydroxyl group, and iii) a second terminal group which is a pharmacokinetic modifying agent. The pharmaceutically active agent is cabazitaxel. The first terminal group is covalently attached to the surface amino group of the dendrimer through a diacid linker, the diacid linker comprising an alkyl chain interrupted by one or more oxygen, sulfur or nitrogen atoms, or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.

Abstract: The present invention provides a special drug conjugate having a hydrophilic acidic stabilization junction. Compared with a conjugate having a lower drug loading, due to the introduction of the acidic stabilization junction, the conjugate in the present invention can also have a higher drug loading (that is, each targeted reagent has more hydrophilic drug junctions), keeps a desired PK property and has a same or better activity in a body.

Abstract: Provided herein are activatable antibodies that specifically bind to CD166 and conjugated activatable antibodies that specifically bind to CD166. Also provided are methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: Antibodies having modified constant regions so as to permit conjugation of the antibody to a payload such as a therapeutic agent are described. Preferred antibodies include a mutation at light chain position 180 (positional numbering), most preferably the mutation is to a residue selected from C, K, Q, or a non-natural amino acid. Additional mutations may also be combined with a mutation at position 180; including one or more of light chain (LC) S208, LC S171, LC S182, LC A184, LC V191, LC S202, LC S203, LC T206, heavy chain (HC) S160, HC T190, HC S443, HC S447, HC S139, HC S168, HC V170, HC V176, HC T200, HC S445 according to a positional numbering convention.

Abstract: The present invention relates to an antibody carrier based on a gold nanoparticle (AuNP)-aptamer conjugate and a method of preparing the same. The antibody carrier according to the present invention is prepared by binding of an immunoglobulin G (IgG) Fc domain-specific aptamer or a fluorescein isothiocyanate (FITC)-specific aptamer to AuNP, and may effectively deliver an antibody into the cell nucleus, the cytoplasm and mitochondria by specific binding of the antibody to be delivered to the aptamer. In addition, since the AuNP having very low cytotoxicity is used, the antibody carrier is not only harmless to the human body, but may also detect a location in cells easily by reflecting light at various wavelengths, and therefore, it is expected to be effectively used in diagnosis or treatment of a disease.

Abstract: A mitochondrion-targeting protein nanoparticle, containing related information such as an amino acid sequence thereof, a coding nucleic acid sequence, and a vector and a host expression bacterium for the coding nucleic acid. Under the induction of metal ions, the self-assembled protein nanoparticle mentioned above can be obtained by an Escherichia coli expression system. The protein nanoparticle can be applied in cancer diagnosis and treatment. Compared with existing mitochondrion-targeting small molecules (such as TPP and MPP), the protein nanoparticle can achieve properties of tumor enrichment, mitochondrion targeting, increasing of ROS content in cells, induction of cell apoptosis, inhibiting tumor growth, etc.

Abstract: The invention relates generally to a method of treatment for a human genetic disease, such as diseases characterized by unbalanced nucleotide pools, e.g., mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency, using gene therapy. The gene therapy may involve administration of one or more constructs, such as a viral vector, containing a nucleic acid encoding a functional protein. The functional protein may correspond to a nuclear gene. For treatment of TK2 deficiency, the gene therapy may involve administration of one or more constructs, such as a viral vector, containing a nucleic acid encoding a functional TK2 enzyme. The treatment may also involve the administration of pharmacological therapy in conjunction with the gene therapy.

Abstract: The present invention relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as SMA and ALS as well as Pompe disease and lysosomal storage disorders.

Abstract: Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems are disclosed. Certain heptamethine cyanines exhibit renal system specificity, while others exhibit biliary system specificity. The compounds may be used for diagnostic purposes and/or for visualization of renal or biliary systems during surgery.

Abstract: An agent for use in detecting, monitoring, and/or imaging cancer cells and/or cancer cell metastasis, migration, dispersal, and/or invasion, and/or for treating cancer in a subject includes a targeting peptide and at least one of a detectable moiety, therapeutic agent, or a theranostic agent that is directly or indirectly linked to the targeting peptide. The targeting peptide specifically binds to and/or complexes with a proteolytically cleaved extracellular fragment of an immunoglobulin (Ig) superfamily cell adhesion molecule that is expressed by a cancer cell or another cell in the cancer cell microenvironment.

Abstract: The present invention provides a cartridge used for a sterilization device. The cartridge comprises a sterilant container configured to contain a sterilant used for sterilization and an injector receiving the sterilant contained in the sterilant container through the sterilization device and delivering the sterilant to an article to be sterilized.

Abstract: Disclosed is a system for transporting washed medical equipment and packing the washed medical equipment in containers in a sterile processing department. The system comprises: a packing table comprising a first working position for a human operator; an automated washing machine for washing medical equipment; and one or more autonomous transport vehicles for transporting medical equipment to the packing table. The system further comprises a receiving element for receiving a container comprising washed medical equipment, the receiving element being arranged in connection with the packing table, the receiving element being movable between a receiving position and a working position. An autonomous transport vehicle is configured to transport a container comprising washed medical equipment from the automated washing machine to the receiving element, and the receiving element being configured to receive a container comprising washed medical equipment by moving from the working position to the receiving position.

Abstract: A method and a system for generating a fragrance (also referred to herein as perfume) are disclosed. A method may comprise providing a perfume blender machine (100) and cartridges (102) for storing liquid olfactory ingredients (112), the machine comprising dispensing means to dispense olfactory ingredients (112) from the cartridges (102) for generating a fragrance (114); controlling the dispensing means to generate a fragrance (114) based on instructions given by a user on the liquid olfactory ingredients (112) to be blended and the quantity of each; and generating a recipe with the information of the ingredients (112) and their respective quantities which have been used to generate the fragrance.

Abstract: A portable or handhold air purification system, whose air flow pipeline made of highly reflective and low absorptive material for UVC or UVB light acts also as a UV light waveguide, is invented. The system is based on the design concept of maximizing UV light exposure dosage to deactivate all the pollutants in the air flow going through to allow the system to use UVC and/or UVB LED. The system also has some features around the middle point of the air flow path to either further increase light exposure, or clean the air flow through the interaction between the specially designed nano particles and incoming UV light. Moreover, an ozone filter and an air heating devices, with energy either from the heat sink of LED's TEC or a device based on plasmonic resonance induced photothermal effects, are placed near the air outlet of the system for further enhancement. The system is very useful for travelers in the closed environment such as in a airplane, or on a train.

Abstract: Adhesive wound dressing that comprises an absorbent matrix (A) adhering to the central portion of a polyurethane backing (B) having an adhesive layer for the skin, said matrix (A) comprising: a. a breathable and porous polyethylene film at the end designed to come into contact with the wound; b. an absorbent layer made of non-woven fabric adjacent to film a), said absorbent layer consisting of: i. 60-65% viscose ii. 25-30% polyester iii. 5-15% polypropylene; c. a layer of polyethylene inserted between layer b) and a layer d. of hydrophobic polystyrene, the latter being in contact with the central portion of polyurethane backing (B); wherein matrix (A) is impregnated with a solution of one or more polysaccharides or the salts thereof.

Abstract: The invention is directed towards a device, method of using and making the same and more particularly to a sterile, biocompatible, fiber free, foam device configured to be used in various different uses, e.g., medical uses, make-up removal uses, and other uses.

Abstract: A wound dressing includes: a structural material formed into a dressing; at least one immunomodulatory agent associated with the dressing; and a growth factor associated with the dressing. A wound dressing kit includes: a structural material formed into a wound dressing; an immunomodulatory agent; and a growth factor composition, wherein the structural material contains the immunomodulatory agent and/or the immunomodulatory agent is in a separate composition. A method of treating a wound in a tissue includes: applying an immunomodulatory agent to the wound; applying a wound dressing to the wound; and allowing the wound to heal with the immunomodulatory agent and wound dressing. The application of a growth factor can be before, during and/or after applying the wound dressing to the wound.

Abstract: The present invention provides an improved tissue adhesive to repair defects in soft tissue. Following ASTM standard tests, crosslinked methacryloyl-substituted gelatin hydrogels of the present invention (GelSEAL) were shown to exhibit adhesive properties, i.e. wound closure strength, shear resistance and burst pressure, that were superior to clinically used fibrin- and poly(ethylene glycol)-based glues. Chronic in vivo experiments in rats proved GelSEAL to effectively seal large lung leakages without additional sutures or staples, presenting improved performance as compared to fibrin and poly(ethylene glycol) glues. Furthermore, subcutaneous implantation in rats revealed high biocompatibility of GelSEAL as evidenced by low inflammatory host response.

Abstract: Disclosed is a fibrinogen composition. The fibrinogen composition comprises denatured fibrinogen hydrogel having a fibrinogen concentration ranging from 0.1 to 15 wt.-% and a fibrinogen hydrogel forming salt at a concentration less than a threshold concentration to form the fibrinogen hydrogel. In some examples, the fibrinogen composition is dehydrated denatured fibrinogen hydrogel, where the fibrinogen composition comprises salt at a concentration no greater than 20 wt.-%.

Abstract: The present invention relates to a method for constructing a whitlockite coating on a surface of a calcium phosphate-based bioceramic substrate and a resulting coating, wherein the preparation method includes the following steps of: preparing pure calcium phosphate-based bioceramic powder firstly, then pre-firing, shaping and calcining the pure calcium phosphate-based bioceramic powder to obtain a calcium phosphate-based bioceramic substrate, placing the substrate in a solution containing Mg2+, then transferring the substrate to a high-temperature high-pressure reaction kettle for a hydrothermal reaction, and then cleaning and drying the sample to obtain a whitlockite coating.

Abstract: Methods are provided herein for modifying antigenic carbohydrate epitopes within a xenographic bioprosthetic tissue by oxidation of vicinal diols to form aldehydes or acids and subsequence reductive amination of aldehydes to form stable secondary amines, or amidation or esterification of acids to form stable amides or esters. Advantageously, methods provided herein mitigate the antigenicity of the bioprosthetic tissue while leaving the overall tissue structure substantially undisturbed, and thereby enhance the durability, safety and performance of the bioprosthetic implant.

Abstract: Disclosed are electrospun scaffolds and methods of making electrospun fibers and electrospun fiber scaffolds. More particularly, the present disclosure relates to electrospun fibrous scaffolds of decellularized muscle tissue and methods of making fibers and fiber scaffolds by electrospinning.

Abstract: There are provided tissue repair laminates which promote cellular in-growth but also prevent or mitigate tissue adhesion. The laminates comprise a biodegradable polyurethane foam layer which facilitates cellular infiltration and a polyurethane barrier layer which is non-adhesive to tissue. The laminates resist shrinkage under in vivo conditions and possess desirable mechanical properties. The laminates find use in, for example, the repair of herniated tissue, particularly, but not limited to hernias in the abdominal wall.

Abstract: A method of manufacturing a therapeutic material incorporating a soft thermoformable elastomer with a phase change material exhibiting high latent heat of fusion. The compound provides elasticity, softness, formability, and heat over an extended duration and to facilitate prolonged skin contact at elevated temperatures. Used in combination with active ingredients the increased temperature and formability provides enhanced transdermal delivery through the skin. Thermoplastic elastomers may be manufactured by mixing together plasticizing oil, a triblock copolymer, a paraffinic substance and one or more additives, e.g., an antioxidant, an antimicrobial agent, and/or other additives to form a mixture which melted then cooled into the thermoplastic elastomer.

Abstract: A method of manufacturing a medical product having an engineered heparin bioactive matrix for clinical application on a blood contacting surface comprises: a) activating a blood contacting surface of at least one component of a medical device via one of plasma treatment or gas activation; b) assembling the medical product; c) Setting up medical device for wet chemistry in which wet chemistry treatments follows a blood flow path through device; d) enhancing at least the blood contacting surface with a wet chemistry treatment including an aqueous solution having a strong oxidizing agent, such as ammonium persulfate; e) adding a positively charged spacer molecule to at least the blood contacting surface with a wet chemistry treatment including an aqueous solution having a cationic polymer, such as PEI; and f) covalently immobilizing heparin to at least the blood contacting surface with a wet chemistry treatment including heparin, preferably deaminated heparin.

Abstract: A collection system for collecting outflow from a hysteroscopic surgical procedure includes a collection vessel and a mounting stand. The collection vessel defines an internal volume and includes a top portion and a bottom portion. The collection vessel is transitionable between a collapsed configuration and an expanded configuration. The mounting stand includes an upper retainer and a lower retainer. The upper retainer of the mounting stand is configured to retain the top portion of the collection vessel and the lower retainer of the mounting stand is configured to retain the bottom portion of the collection vessel. The upper and lower retainers are configured to retain the collection vessel thereon in the expanded configuration.

Abstract: Systems and methods are disclosed for monitoring for an occlusion in an aspiration line during an ophthalmic surgical procedure. An ophthalmic surgical system may comprise a first aspiration pump located in a handpiece, a second aspiration pump located away from the handpiece such as in a console, and a pressure sensor located between the first aspiration pump and the second aspiration pump. The pressure sensor is adapted to monitor for an occlusion in the aspiration line upstream of the first aspiration pump. The second aspiration pump may be operated at the same flow rate as the first aspiration pump and/or to maintain a constant pressure between the second aspiration pump and the first aspiration pump. Systems and methods as disclosed allow for a handpiece pump located close to the working tip while providing reliable occlusion detection with a pressure sensor located away from the handpiece.

Abstract: Systems and methods are disclosed for reducing pulsations in peristaltic pumps. In some examples, a cassette comprises a cassette body and a flexible sheet joined to the cassette body, wherein a transition region of the flexible sheet comprises at least one ridge that has a maximum height at a position that is offset from a center line of a cassette body transition channel. In some examples, a cassette body transition channel comprises side walls that taper toward an active region of the fluid path and/or toward a bottom of the transition channel. An example method of operating a peristaltic pump comprises operating rollers at a higher speed during portions of a revolution that otherwise would result in a lower than average flow rate and at a lower speed during portions of the revolution that otherwise would result in a higher than average flow rate.

Abstract: A reduced-pressure treatment system for applying reduced pressure to a tissue site at a limited-access location on a patient includes a reduced-pressure source, a treatment manifold for placing proximate the tissue site and operable to distribute reduced pressure to the tissue site, and a sealing member for placing over the tissue site and operable to form a pneumatic seal over the tissue site. The reduced-pressure treatment system also includes a reduced-pressure bridge and a moisture-removing device on at least portion of the reduced-pressure bridge. The reduced-pressure bridge includes a delivery manifold operable to transfer the reduced pressure to the treatment manifold, an encapsulating envelope at least partially enclosing the delivery manifold and having a patient-facing side, and a reduced-pressure-interface site formed proximate one end of the reduced-pressure bridge.

Abstract: A bearing assembly is configured to retain a distal end of an impeller of a blood pump, where the impeller includes a drive shaft. The bearing assembly includes a pivot member coupled to a distal end of the drive shaft; a distal bearing cup having a proximally-facing surface configured to engage at least a portion of a distal section of the pivot member; and a sleeve bearing disposed around at least a portion of a proximal section of the pivot member.

Abstract: The present invention provides compositions which can be used to treat a carrier protein-containing multiple pass dialysis fluid in particular in order to ensure regeneration of a carrier protein such as albumin in the dialysis fluid. The invention further relates to kits comprising such compositions and uses thereof as well as to methods for providing and regenerating a carrier protein-containing multiple pass dialysis fluid.

Abstract: The present invention is to provide a means capable of properly balancing water and sodium in peritoneal dialysis treatment, without causing hyponatremia, while avoiding adversely affecting residual renal function. A peritoneal dialysate containing 1.5 to 1.8 w/v % of glucose and 120 to 130 mEq/L of sodium, and being for independent use once or twice a day, wherein the peritoneal dialysate is used in combination with another peritoneal dialysate that contains 1.35 to 2.5 w/v % of glucose and 132 to 135 mEq/L of sodium, in peritoneal dialysis that involves injection of an amount of 1.5 to 2.0 L per one time in an abdominal cavity of a subject, storage and drainage three to five times a day.

Abstract: Methods and systems for the automated collection of plasma from a donor are disclosed. The methods and systems deliver anticoagulant to whole blood and/or to selected and separated components at selected times to provide a sufficient amount of anticoagulant to the selected components to prevent coagulation and/or flocculation. The methods and systems limit the amount of anticoagulant returned to the donor and maximize the amount of collected plasma. Methods and systems for maximize the collection of IgG based on a measured level of total plasma protein are also disclosed.

Abstract: A fluid temperature control device for an extracorporeal blood treatment apparatus, comprises: a casing (26) delimiting a heating/cooling seat (20) configured to accommodate a fluid warming bag (17) connected or connectable to an extracorporeal blood treatment apparatus (1); heating elements (29, 30) operatively active in the heating seat (20) to heat the fluid warming bag (17); at least a presence detector (32, 33) operatively active in the heating seat (20) to detect the presence of the fluid warming bag (17). The presence detector (32, 33) comprises an electromagnetic transmitter (34) and an electromagnetic receiver (35).

Abstract: Techniques and apparatus for de-priming processes are described. For example, in one embodiment, an apparatus may include at least one processor and a memory coupled to the at least one processor, the memory may include instructions that, when executed by the processor, may cause the at least one processor to determine a priming volume of a primer fluid infused into a priming system associated with the patient during a priming phase of the dialysis treatment, cause an ultrafiltration rate of an ultrafiltration pump of the dialysis machine in fluid communication with the patient to be changed from a treatment ultrafiltration rate to a de-priming ultrafiltration rate to remove the priming volume over a de-priming time period, and cause, after the de-priming time period, the ultrafiltration rate of the ultrafiltration pump to be changed back the treatment ultrafiltration rate. Other embodiments are described.

Abstract: A connector arrangement (10) for connecting to a fluid chamber (6) of a blood treatment unit (4) for extracorporeal blood treatments. The connector arrangement (10) includes a connector device (11) with a connector body (47) comprising a port opening (43) and an interior wall (50) defining a port space (39) designed to receive a first fluid port (8A) of the fluid chamber (6). The connector device (11) also incorporates a fluid path (35a) extending from the port space (39) to a first end opening (51) of the connector device (11), and an air path (36a) extending from the port space (39) to a second end opening (52) of the connector device (11), wherein the fluid path (35a) and the air path (36a) are separate paths. Also a system (1) for extracorporeal blood treatment including the connector arrangement (10) and a method for priming the fluid chamber (6).

Abstract: A perfusion container for directly administering to patients a dose of an antineoplastic drug calculated according to a patient's parameter, wherein the first perfusion container comprises a solution of antineoplastic drug at a concentration and volume such that the amount of antineoplastic drug in the container is equal to the calculated dose for one patient but less than the calculated dose for a second patient, the calculated dose is provided to first patient within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container, further the first perfusion container is accompanied by a second top-up perfusion container comprising a solution of antineoplastic drug at a concentration and volume such that the calculated dose is provided within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container and the second top-up container to the second patient.

Abstract: A compact infusion device that is easily portable and inexpensive, can be used safely, and can provide a technique alternative to intravenous drip. The portable compact infusion device includes a fluid drive, a fluid holding portion, a drug solution holding channel, and a support, wherein the fluid drive includes a porous body that allows generation of electroosmotic flow and a pair of rubber electrodes each containing electroconductive material and having a communicating portion, the porous body being sandwiched between the communicating portions of the pair of rubber electrodes to form a sandwiched structure.

Abstract: An infusion pump includes a core member and a bladder member which are substantially spheroidal at one end and cylindrical at the other end. The core member is inserted inside the bladder member and a ring member engages the cylindrical ends of the core and bladder member to sealingly secure the bladder to the core. A tubular hose is included and is coupled with an infusion port of the core member. When fluid is injected into the pump, it causes the bladder member to inflate substantially symmetrically and spherically around an axial axis of the core member. Upon deflating the bladder member, the fluid is ejected out of the pump at a constant flow rate.

Abstract: Devices that are placed within fluid filled organs, such as the bladder, which reduce the risk of bacterial infections using a combination of active agents and mechanical disruption of bacteria.

Abstract: A controller and associated sensor system for augmenting the automatic delivery of drugs is provided. The controller and associated sensor system is based on the detection and determination of particular physical lifestyle events. As a specific example, a pump augmentation system includes a six-axis accelerometer sensor, a gyroscopic pitch sensor and a controller. The controller is configured to receive motion data from the six-axis accelerometer sensor and orientation data from the gyroscopic pitch sensor. The controller provides a pump instruction signal for changing a delivery rate of a drug to a user based on the motion data and the orientation data. When the pump is an insulin pump, the pump augmentation system is an insulin pump augmentation system and provides accurate insulin control for controlling blood glucose levels of a user.

Abstract: Systems and methods for treating hypoglycemia generally comprise a processor and a medicament injection unit. A processor may receive continuous glucose sensor data indicative of a host's blood glucose concentration. The processor may determine whether a host's blood glucose concentration is below a predetermined threshold setting. Based at least in part on the host's blood glucose concentration, the medicament injection unit may be configured to administer a medicament to the host.

Abstract: A dual chamber syringe, comprising a syringe barrel having a forward end, a rearward end and at least one bypass protrusion arranged along the longitudinal extent of the syringe barrel; a finger grip element coupled to the rearward end of the syringe barrel, the finger grip comprises at least one protrusion extending radially inwardly from an inner surface thereof; a plunger rod operatively coupled with the finger grip element; a guiding track is formed on the plunger rod and comprises a helical track portion and a longitudinal track portion; and wherein upon relative displacement of the plunger rod and said finger grip element, the at least one protrusion is guided along the guiding track.